GlobeNewswire·Nov 9, 2025, 9:00 AM ET

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Monopar Therapeutics Inc. presented new data from the Phase 2 ALXN1840-WD-204 copper balance study at the AASLD Liver Meeting 2025 in Washington, D.C.
Professor Aftab Ala presented oral findings showing ALXN1840 (tiomolybdate choline) rapidly improved daily copper balance in Wilson disease patients primarily via increased fecal copper excretion.
The study involving 8 patients demonstrated significantly lower mean daily copper balance compared to baseline during the 15 mg once-daily dosing period (days 1-28) and across the entire treatment duration (days 1-39).
Additional nonclinical & clinical data from the ALXN1840-WD-204 study supporting these copper balance improvements were also shared.
Monopar holds late-stage status for ALXN1840 in Wilson disease alongside Phase 1 imaging programs (MNPR-101-Zr) & Phase 1a/late preclinical therapeutic programs (MNPR-101-Lu, MNPR-101-Ac225) for advanced cancers.
Presentation materials are available on Monopar's website with the abstract accessible via the AASLD conference site.